Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million.

Tome Biosciences, a new genome editing company, emerged from stealth on Tuesday and announced that it has raised $213 million between its Series A and B financing rounds.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

Eli Lilly and Verve Therapeutics on Thursday said they have entered into an exclusive research collaboration to advance a preclinical gene-editing therapy for atherosclerotic cardiovascular disease (ASCVD) into the clinical stage.